Piramal Pharma turns profitable; consolidated PAT ₹5.6 Cr as OPM expands to 13.3%

Piramal Pharma's consolidated revenue rose 28.1% YoY (₹2,617.1 Cr vs ₹2,043.7 Cr) and 15.3% QoQ (vs ₹2,269.9 Cr), and the company returned to profit after two straight quarterly losses — consolidated PAT attributable to owners was ₹5.6 Cr versus losses of ₹99.2 Cr a year ago and ₹69.4 Cr last quarter. No exceptional items were booked this quarter (unlike FY26's ₹196.1 Cr full-year exceptional charge), so the swing is entirely operational rather than one-off-driven. The turnaround was margin-led: consolidated OPM (EBITDA/revenue) expanded to 13.3% from 7.8% a year ago and 8.6% last quarter — a roughly 557bps YoY gain — as operating leverage kicked in on the higher revenue base. Net margin, however, stayed wafer-thin at 0.21%, since finance costs (₹87.6 Cr) and depreciation/amortisation (₹233.2 Cr) — both elevated by the ongoing Lexington sterile-injectable buildout — continue to absorb most of the operating gain. Standalone PAT, by contrast, came in at ₹170.7 Cr on standalone revenue of ₹1,345.4 Cr; the wide gap versus the ₹5.6 Cr consolidated figure reflects that overseas subsidiaries, which carry the bulk of the group's debt, D&A and the newly consolidated minority interest, are still near breakeven even as the India entity is comfortably profitable — readers should treat the consolidated number as the primary read. Revenue growth of 28% YoY runs well ahead of management's maintained FY27 guidance of mid-teen revenue growth from the Q1 call, and the OPM trajectory is consistent with the stated path to a 25% EBITDA margin by FY30. No Q2-specific brokerage consensus was found ahead of this print; full-year FY27 PAT estimates from Choice Equity Broking (~₹140 Cr) and Motilal Oswal (~₹110 Cr, adjusted) imply H2 needs to deliver roughly ₹175–205 Cr given H1FY27's cumulative owners' loss of ₹63.8 Cr — a step-up not yet evidenced on a single quarterly print. During the quarter PPL completed the acquisition of an incremental 40.67% stake in Yapan Bio, a Hyderabad CDMO, for ₹76.1 Cr, taking its holding to 74% and triggering first-time NCI consolidation (provisional goodwill, pending final purchase-price allocation); the company also flagged the Bayer distribution deal ending in 2026 and clarified that funding tied to its Ontario site is not material, though neither carries a quantified P&L impact in this filing. No standalone press release accompanied the filing to cross-check management's own framing of the quarter. With H1FY27 still showing a cumulative owners' loss of ₹63.8 Cr, H2 profitability — and whether the 13.3% OPM holds or extends — is now the number that determines whether the FY27 guidance trajectory stays credible.